Barrett's esophagus and esophageal cancer: an overview.
暂无分享,去创建一个
[1] N. Barrett. Chronic peptic ulcerz of the œophagus and ‘œsophagitis’ , 1950 .
[2] N R BARRETT,et al. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. , 1950, The British journal of surgery.
[3] P. Allison,et al. The Oesophagus Lined with Gastric Mucous Membrane , 1953, Thorax.
[4] M. Savary,et al. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. , 1975, The Journal of thoracic and cardiovascular surgery.
[5] R. Sampliner,et al. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.
[6] A. Blum,et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification , 1999, Gut.
[7] Stanley R. Hamilton,et al. Pathology and genetics of tumours of the digestive system , 2000 .
[8] P. Dítě,et al. [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.
[9] M F Dixon,et al. The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.
[10] P. Enzinger,et al. Esophageal cancer. , 2003, The New England journal of medicine.
[11] A. Bhattacharyya,et al. Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus , 2004, American Journal of Gastroenterology.
[12] K. McColl,et al. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux , 2004, Gut.
[13] D. Parkin. International variation , 2004, Oncogene.
[14] Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice , 2004, Gut.
[15] H. Welch,et al. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.
[16] Michael Vieth,et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. , 2005, Gastroenterology.
[17] J. Slack,et al. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. , 2005, Developmental biology.
[18] J. Dent,et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review , 2005, Gut.
[19] H. Comber,et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. , 2006, Cancer research.
[20] R. Playford. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus , 2006, Gut.
[21] J. Dent,et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.
[22] R. Sampliner,et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus , 2006, Gut.
[23] R. Elston,et al. Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction , 2006, Cancer Epidemiology, Biomarkers and Prevention.
[24] Michael Vieth,et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. , 2006, Gastroenterology.
[25] Kamran Ayub,et al. NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.
[26] J. Soares,et al. Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved , 2007, Modern Pathology.
[27] R. Fitzgerald,et al. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. , 2007, Gastroenterology.
[28] C. V. Van Itallie,et al. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[29] W. Phillips,et al. Identification of Candidate Murine Esophageal Stem Cells Using a Combination of Cell Kinetic Studies and Cell Surface Markers , 2007, Stem cells.
[30] A. Shar,et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.
[31] J. Tack,et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces , 2007, Gut.
[32] J A Jankowski,et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus , 2008, Gut.
[33] Edward L. Lee,et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[34] N. Nishioka,et al. Patient predictors of esophageal stricture development after photodynamic therapy. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[35] Kenneth K Wang,et al. Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.
[36] Kenneth J. Chang,et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. , 2008, Gastrointestinal endoscopy.
[37] Patricia L. Blount,et al. Single Nucleotide Polymorphism–Based Genome-Wide Chromosome Copy Change, Loss of Heterozygosity, and Aneuploidy in Barrett's Esophagus Neoplastic Progression , 2008, Cancer Prevention Research.
[38] W. Phillips,et al. Esophageal Stem Cells—A Review of Their Identification and Characterization , 2008, Stem Cell Reviews.
[39] N. Shaheen,et al. Multilayered epithelium in a rat model and human Barrett's esophagus: Similar expression patterns of transcription factors and differentiation markers , 2008 .
[40] N. Hayward,et al. Leptin and the risk of Barrett’s oesophagus , 2007, Gut.
[41] G. Block,et al. Dietary Antioxidants, Fruits, and Vegetables and the Risk of Barrett's Esophagus , 2008, The American Journal of Gastroenterology.
[42] L. Gossner,et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus , 2008, Gut.
[43] D. Buckles,et al. Treatment of Barrett’s esophagus with high-grade dysplasia , 2009, Expert review of anticancer therapy.
[44] N. Shaheen,et al. Association of adiponectin multimers with Barrett’s oesophagus , 2009, Gut.
[45] Prateek Sharma,et al. How to manage a Barrett's esophagus patient with low-grade dysplasia. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[46] R. Goyal,et al. Metaplastic Esophageal Columnar Epithelium Without Goblet Cells Shows DNA Content Abnormalities Similar to Goblet Cell–Containing Epithelium , 2009, The American Journal of Gastroenterology.
[47] Prateek Sharma,et al. Clinical practice. Barrett's esophagus. , 2009, The New England journal of medicine.
[48] G. Block,et al. Effects of Dietary Fiber, Fats, and Meat Intakes on the Risk of Barrett's Esophagus , 2009, Nutrition and cancer.
[49] P. Malfertheiner,et al. Chemoprevention of Adenocarcinoma Associated with Barrett’s Esophagus: Potential Options , 2009, Digestive Diseases.
[50] J. Jankowski,et al. Chemoprevention of oesophageal cancer and the AspECT trial. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[51] R. Cestari,et al. HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study , 2008, Journal of cellular and molecular medicine.
[52] A. Bhattacharyya,et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] J. Ajani,et al. Constitutive Short Telomere Length of Chromosome 17p and 12q but not 11q and 2p Is Associated with an Increased Risk for Esophageal Cancer , 2009, Cancer Prevention Research.
[54] S. Ishihara,et al. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett’s epithelium development , 2009, Gut.
[55] R. Hunt,et al. Helicobacter pylori Infection and Barrett's Esophagus: A Systematic Review and Meta-Analysis , 2009, The American Journal of Gastroenterology.
[56] R. K. Pearson. Radiofrequency Ablation in Barrett's Esophagus with Dysplasia , 2009 .
[57] H. Clevers,et al. Indian hedgehog regulates intestinal stem cell fate through epithelial-mesenchymal interactions during development. , 2010, Gastroenterology.
[58] Prateek Sharma,et al. Advances in endoscopic diagnosis and treatment of Barrett's esophagus , 2010, Journal of digestive diseases.
[59] R. Elston,et al. A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[60] L. Murray,et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. , 2010, Gastroenterology.
[61] C. Hawkey,et al. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis , 2010, Endoscopy.
[62] J. Freund,et al. CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype , 2010, Gut.
[63] Kenneth K Wang,et al. Barrett esophagus: an update , 2010, Nature Reviews Gastroenterology &Hepatology.
[64] Z. Zhao,et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. , 2010, Gastroenterology.
[65] A. Dabrowski,et al. Magnification Endoscopy and Chromoendoscopy in Evaluation of Specialized Intestinal Metaplasia in Barrett’s Esophagus , 2011, Digestive Diseases and Sciences.
[66] R. Pearson. Endoscopic and Surgical Treatment of Mucosal (T1a) Esophageal Adenocarcinoma in Barrett's Esophagus , 2010 .
[67] F. Willingham,et al. Review: Diagnosis and management of Barrett’s esophagus for the endoscopist , 2010, Therapeutic advances in gastroenterology.
[68] R. Fitzgerald,et al. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. , 2010, World journal of gastroenterology.
[69] D. L. Wilburn,et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. , 2010, Gastroenterology.
[70] J. Slack,et al. The role of Cdx2 in Barrett's metaplasia. , 2010, Biochemical Society transactions.
[71] S. Spechler,et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. , 2010, Gastroenterology.
[72] J. Dent. Barrett's esophagus: A historical perspective, an update on core practicalities and predictions on future evolutions of management , 2011, Journal of gastroenterology and hepatology.
[73] J. Lynch,et al. Ectopic Cdx2 Expression in Murine Esophagus Models an Intermediate Stage in the Emergence of Barrett's Esophagus , 2011, PloS one.
[74] J. Jankowski,et al. Chemoprevention in Barrett's esophagus: A pill a day? , 2011, Gastrointestinal endoscopy clinics of North America.
[75] E. Kuipers,et al. Predictors for Neoplastic Progression in Patients With Barrett's Esophagus: A Prospective Cohort Study , 2011, The American Journal of Gastroenterology.
[76] D. Whiteman,et al. Barrett's esophagus , 2011, Journal of gastroenterology and hepatology.
[77] Prateek Sharma,et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.
[78] N. Shaheen,et al. The role of radiofrequency ablation in the management of Barrett's esophagus. , 2011, Gastrointestinal endoscopy clinics of North America.
[79] J. Dent,et al. Helicobacter pylori infection and gastritis: The Systematic Investigation of gastrointestinaL diseases in China (SILC) , 2011, Journal of gastroenterology and hepatology.
[80] Hiroshi Mashimo,et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. , 2011, Gastroenterology.
[81] Prateek Sharma,et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.
[82] E. Montgomery,et al. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia. , 2011, Archives of pathology & laboratory medicine.
[83] A. Jemal,et al. Global Cancer Statistics , 2011 .
[84] P. Kahrilas. The problems with surveillance of Barrett's esophagus. , 2011, The New England journal of medicine.
[85] Quan P. Ly,et al. Esophageal and esophagogastric junction cancers. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[86] Jesper Lagergren,et al. Influence of obesity on the risk of esophageal disorders , 2011, Nature Reviews Gastroenterology &Hepatology.
[87] K. Washington,et al. Endoscopic therapy of esophageal premalignancy and early malignancy. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[88] D. Christiani,et al. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. , 2011, Neoplasia.
[89] A. Gavin,et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.
[90] K. Behrns,et al. Incidence of Adenocarcinoma among Patients with Barrett's Esophagus , 2012 .